SUBSCRIBE
SUBSCRIBE

Kyverna Therapeutics

NEWS
Business
Intellia and Kyverna to Leverage CAR-T Therapy Against Autoimmune Diseases
Intellia and Kyverna announced an exclusive agreement to develop and later commercialize an allogeneic CD19 CAR T-cell therapy to treat a wide range of B cell-mediated autoimmune illnesses.
January 5, 2022
 · 
2 min read
 · 
Vanessa Doctor, RN
Courtesy of Jer123/Getty Images
Business
Kyverna Tries NIH Cell Therapy for Autoimmune Disease
This California biotech just bagged another partner for its endeavor to cure autoimmune disease with cell therapy.
January 3, 2022
 · 
2 min read
 · 
Kate Goodwin
Look at these top life science startups.
Pharm Country
Top Life Science Startups to Watch in 2021
BioSpace is proud to present its NextGen Bio “Class of 2021,” a list of up-and-coming life science startups in North America that recently launched.
January 5, 2021
 · 
16 min read
 · 
Mark Terry
Load More
AWARDS
  • NextGen Class of 2021
JOBS
IN THE PRESS
Press Releases
Kyverna Therapeutics Provides Corporate Update and Outlines 2026 Strategic Priorities at the J.P. Morgan Healthcare Conference
January 12, 2026
 · 
8 min read
Press Releases
Kyverna Therapeutics to Present at the J.P. Morgan 2026 Healthcare Conference
January 5, 2026
 · 
1 min read
Press Releases
Kyverna Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock
December 18, 2025
 · 
4 min read
Press Releases
Kyverna Therapeutics Announces Proposed Public Offering of Common Stock
December 16, 2025
 · 
4 min read
Press Releases
Kyverna Therapeutics Announces Positive Topline Data from Registrational KYSA-8 Trial of Miv-cel (KYV-101) in Stiff Person Syndrome
December 15, 2025
 · 
11 min read
Press Releases
Kyverna Therapeutics to Report Topline Results from Registrational Phase 2 KYSA-8 Trial of KYV-101 in Stiff Person Syndrome
December 15, 2025
 · 
3 min read
Press Releases
Kyverna Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results
November 13, 2025
 · 
12 min read
Press Releases
Kyverna Therapeutics to Present at the Jefferies London Healthcare Conference
November 11, 2025
 · 
1 min read
Press Releases
Kyverna Therapeutics Secures up to $150 Million in Non-Dilutive Financing from Oxford Finance
November 4, 2025
 · 
6 min read
Press Releases
Kyverna Therapeutics Announces Positive Interim Phase 2 Data from KYSA-6 Study of KYV-101 in Generalized Myasthenia Gravis at AANEM 2025
October 29, 2025
 · 
10 min read
Load More